Full Press Release Details
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue
CAMBRIDGE, Mass., Jan. 13, 2025 Sarepta Therapeutics, Inc. (NASDAQ:SRPT),
the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2024 net product revenue and cash on hand as of December 31, 2024, as part of its presentation today at the 43rd Annual J.P.
Morgan Healthcare Conference in San Francisco, Calif.
Financial Update* (preliminary and unaudited):
2024 marked the most significant year to date for Sarepta and for the patients we serve. And consistent with our long track
record of execution, we ended 2024 and enter 2025 with exceptionally strong performance, said Doug Ingram, president and chief executive officer, Sarepta Therapeutics. In the fourth quarter, we grew total product revenue by 75%
year-over-year and grew ELEVIDYS by a very robust 112% over the prior sequential quarter, overachieving our guidance by more than $60 million. Our 2024 total net product revenue grew some 56% over 2023. And we were pleased to see that even in
the face of a strong ELEVIDYS launch, our PMO franchise continued to perform and grow year-over-year.
About ELEVIDYS (delandistrogene moxeparvovec-rokl)
ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to
address the underlying genetic cause of Duchenne muscular dystrophy mutations or changes in the DMD gene that result in the lack of dystrophin protein through the delivery of a transgene that codes for the targeted production of
ELEVIDYS micro-dystrophin in skeletal muscle.
ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years
The DMD indication in non-ambulatory patients is approved under accelerated
approval based on expression of ELEVIDYS micro-dystrophin (noted hereafter as micro-dystrophin ) in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a
confirmatory trial(s).
IMPORTANT SAFETY INFORMATION
CONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene.
WARNINGS AND PRECAUTIONS:
Infusion-related Reactions:
Acute Serious Liver Injury:
Immune-mediated Myositis:
Preexisting Immunity against AAVrh74:
Report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch
or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).
For further information, please see the full Prescribing Information.
About Sarepta Therapeutics
urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have
more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or
Internet Posting of Information
We routinely post information that may be important to investors in the For Investors section of our website at www.sarepta.com. We
encourage investors and potential investors to consult our website regularly for important information about us.
Forward-Looking Statements
This press release contains forward-looking statements. Any statements that are not statements of historical fact may be deemed to
be forward-looking statements. Words such as believe, anticipate, plan, expect, will, may, intend, prepare, look, potential,
possible and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to our expected financial results.
These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta s
control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: the estimates and judgments we make, or the
assumptions on which we rely, in preparing our consolidated financial statements could prove inaccurate; our revenues and operating results could fluctuate significantly, which may adversely affect our stock price; and those risks identified under
the heading Risk Factors in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 as well as other SEC filings made by the Company which you are encouraged to review.
Any of the foregoing risks could materially and adversely affect the Company s business, results of operations and the trading price of
Sarepta s common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements
contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law.
Source: Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
Tracy Sorrentino, 617-301-8566